Ccc_R08

• Description:

  Ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection[1][2].

• UNSPSC:

  12352005

• Target:

  DNA/RNA Synthesis; HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ccc-r08.html

• Concentration:

  10mM

• Purity:

  98.87

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C (C2=CC=C (OCCOC3CC (C (O) =O) C3) C=C2) OC4=C1C=CC=C4Cl

• Molecular Formula:

  C22H19ClO6

• Molecular Weight:

  414.84

• References & Citations:

  [1]Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278 (22) 03466-3. |[2]Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19 (3) :235-244.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2919019-72-8